We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KERX
151
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$554K 0.04%
549
-365
-40% -$3.25K
PRTK
152
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$552K 0.04%
14,458
-2,378
-14% -$85.1K
PRTK
153
PUT
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$551K 0.04%
144
– –
ECYT
154
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$547K 0.04%
+410
New +$6.48K
ONXX
155
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
$504K 0.03%
+4,045
New +$512K
IONS icon
156
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$488K 0.03%
130
-880
-87% -$26.3K
KBIO
157
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$476K 0.03%
+13,176
New +$600K
SLXP
158
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$473K 0.03%
+7,073
New +$487K
LITS
159
CALL
Lite Strategy Inc
LITS
$33M
$454K 0.03%
+20
New +$3.13K
BCRX icon
160
CALL
BioCryst Pharmaceuticals
BCRX
$2.48B
$446K 0.03%
+613
New +$3.11K
IONS icon
161
Ionis Pharmaceuticals
IONS
$9.14B
$438K 0.03%
+11,663
New +$348K
DNDN
162
PUT
DELISTED
DENDREON CORPORATION
DNDN
$421K 0.03%
1,436
-264
-16% -$977
CBST
163
PUT
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$394K 0.03%
+62
New +$3.75K
KERX
164
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$383K 0.02%
37,890
-707,545
-95% -$6.3M
GERN icon
165
CALL
Geron
GERN
$930M
$376K 0.02%
+1,187
New +$1.95K
ACOR
166
CALL
DELISTED
Acorda Therapeutics
ACOR
$369K 0.02%
1
-26
-96% -$112K
PATH
167
PUT
DELISTED
NUPATHE INC COM STK
PATH
$369K 0.02%
+1,531
New +$4.09K
GERN icon
168
Geron
GERN
$930M
$366K 0.02%
+115,719
New +$190K
NBIX icon
169
Neurocrine Biosciences
NBIX
$18.4B
$361K 0.02%
+218,849
New +$3.01M
PLUR icon
170
PUT
Pluri
PLUR
$18.1M
$351K 0.02%
+13
New +$3.24K
OREX
171
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$345K 0.02%
56
+12
+27% +$813
FBIO icon
172
PUT
Fortress Biotech
FBIO
$113M
$304K 0.02%
29
+7
+32% +$858
CYBX
173
DELISTED
CYBERONICS INC
CYBX
$303K 0.02%
5,977
-156,648
-96% -$8.22M
EWJ icon
174
iShares MSCI Japan ETF
EWJ
$21.3B
$298K 0.02%
+6,250
New +$289K
AVNR
175
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$282K 0.02%
66,518
-183,482
-73% -$869K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.